These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 11594337)

  • 1. Surveillance or surgery? A description of the factors that influence high risk premenopausal women's decisions about prophylactic oophorectomy.
    Hallowell N; Jacobs I; Richards M; Mackay J; Gore M
    J Med Genet; 2001 Oct; 38(10):683-91. PubMed ID: 11594337
    [No Abstract]   [Full Text] [Related]  

  • 2. Characterizing biased cancer-related cognitive processing: relationships with BRCA1/2 genetic mutation status, personal cancer history, age, and prophylactic surgery.
    Carpenter KM; Eisenberg S; Weltfreid S; Low CA; Beran T; Stanton AL
    Health Psychol; 2014 Sep; 33(9):1003-11. PubMed ID: 23772886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Socio-demographic and clinical profile of BRCA1/2 mutation carriers opting for prophylactic oophorectomy.
    Dagan E; Gil S; Gershoni-Baruch R
    Prev Med; 2008 May; 46(5):470-2. PubMed ID: 18255133
    [No Abstract]   [Full Text] [Related]  

  • 4. High-risk premenopausal women's experiences of undergoing prophylactic oophorectomy: a descriptive study.
    Hallowell N; Mackay J; Richards M; Gore M; Jacobs I
    Genet Test; 2004; 8(2):148-56. PubMed ID: 15345112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Women's constructions of the 'right time' to consider decisions about risk-reducing mastectomy and risk-reducing oophorectomy.
    Howard AF; Bottorff JL; Balneaves LG; Kim-Sing C
    BMC Womens Health; 2010 Aug; 10():24. PubMed ID: 20687957
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of proband mediated information dissemination in families with a BRCA1/2 gene mutation.
    Sermijn E; Goelen G; Teugels E; Kaufman L; Bonduelle M; Neyns B; Poppe B; De Paepe A; De Grève J
    J Med Genet; 2004 Mar; 41(3):e23. PubMed ID: 14985394
    [No Abstract]   [Full Text] [Related]  

  • 7. Impact of family history on choosing risk-reducing surgery among BRCA mutation carriers.
    Singh K; Lester J; Karlan B; Bresee C; Geva T; Gordon O
    Am J Obstet Gynecol; 2013 Apr; 208(4):329.e1-6. PubMed ID: 23333547
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Breast Cancer Risk Reduction Decisions of the BRCA-Positive Patient: An Observational Study at a Single Institution.
    Johns D; Agarwal J; Anderson L; Ying J; Kohlmann W
    J Womens Health (Larchmt); 2017 Jun; 26(6):702-706. PubMed ID: 27922795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRCA1 genetic mutation and its link to ovarian cancer: implications for advanced practice nurses.
    Brunsvold AN; Wung SF; Merkle CJ
    J Am Acad Nurse Pract; 2005 Dec; 17(12):518-26. PubMed ID: 16293160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surgical risk reduction: prophylactic salpingo-oophorectomy and prophylactic mastectomy.
    Dowdy SC; Stefanek M; Hartmann LC
    Am J Obstet Gynecol; 2004 Oct; 191(4):1113-23. PubMed ID: 15507929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distinctive psychological and social experiences of women choosing prophylactic oophorectomy for cancer prevention.
    Meadows R; Padamsee TJ; Paskett ED
    Health Care Women Int; 2018 May; 39(5):595-616. PubMed ID: 29319429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of personal medical history and family history of cancer on the uptake of risk-reducing salpingo-oophorectomy.
    van der Aa JE; Hoogendam JP; Butter ES; Ausems MG; Verheijen RH; Zweemer RP
    Fam Cancer; 2015 Dec; 14(4):539-44. PubMed ID: 26264902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of prophylactic salpingo-oophorectomy on quality of life and psychological distress in women with a BRCA mutation.
    Finch A; Metcalfe KA; Chiang J; Elit L; McLaughlin J; Springate C; Esplen MJ; Demsky R; Murphy J; Rosen B; Narod SA
    Psychooncology; 2013 Jan; 22(1):212-9. PubMed ID: 21913283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium.
    Burke W; Daly M; Garber J; Botkin J; Kahn MJ; Lynch P; McTiernan A; Offit K; Perlman J; Petersen G; Thomson E; Varricchio C
    JAMA; 1997 Mar; 277(12):997-1003. PubMed ID: 9091675
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bilateral prophylactic oophorectomy and ovarian cancer screening following BRCA1/BRCA2 mutation testing.
    Schwartz MD; Kaufman E; Peshkin BN; Isaacs C; Hughes C; DeMarco T; Finch C; Lerman C
    J Clin Oncol; 2003 Nov; 21(21):4034-41. PubMed ID: 14581427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Maximising survival: the main concern of women with hereditary breast and ovarian cancer who undergo genetic testing for BRCA1/2.
    Jeffers L; Morrison PJ; McCaughan E; Fitzsimons D
    Eur J Oncol Nurs; 2014 Aug; 18(4):411-8. PubMed ID: 24731853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A qualitative study of the information needs of high-risk women undergoing prophylactic oophorectomy.
    Hallowell N
    Psychooncology; 2000; 9(6):486-95. PubMed ID: 11180583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Familial breast and ovarian cancers.
    Arai M; Utsunomiya J; Miki Y
    Int J Clin Oncol; 2004 Aug; 9(4):270-82. PubMed ID: 15375703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lessons learned from genetic testing.
    Esserman L; Kaklamani V
    JAMA; 2010 Sep; 304(9):1011-2. PubMed ID: 20810382
    [No Abstract]   [Full Text] [Related]  

  • 20. Prophylactic surgery decisions and surveillance practices one year following BRCA1/2 testing.
    Lerman C; Hughes C; Croyle RT; Main D; Durham C; Snyder C; Bonney A; Lynch JF; Narod SA; Lynch HT
    Prev Med; 2000 Jul; 31(1):75-80. PubMed ID: 10896846
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.